Thus, the therapeutic effect of simultaneously blocking VEGF-B and IL-17A signaling pathways with their neutralizing antibodies was evaluated for the first time in leptin-receptor-deficient db/db mice, a robust and progressive DKD animal model. The gene discussed is IL17A; the disease is diabetic kidney disease.